Patients with missense mutations (type 2 VHL) exhibit a higher prevalence of pancreatic tumors and a hotspot on codons 161/67 in exon 3 is associated with higher risk of metastases compared to truncating mutations or large deletions (type 1 VHL) (144). Here, VHL is linked to pancreatic neoplasm.